call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Middle East Liquid Biopsy Market
Inquire Before Buying Request for Sample

Middle East Liquid Biopsy Market

Home Healthcare And Pharmaceutical Middle East Liquid Biopsy Market

Middle East Liquid Biopsy Market - By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Other Technologies); By Work Flow (Sample Preparation, Library Preparation, Sequencing, Data Analysis); By Usage (Research Use Only (RUO), Clinical); By Sample (Blood, Urine, Saliva); By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles, Other Circulating Biomarkers); By Product (Tests/Services, Kits and Consumables, Instruments), Trend Analysis, Competitive Landscape & Forecast, 2019–2029

  • Published Date: January 2023
  • Report ID: BWC23008
  • Available Format: PDF
  • Page: 240

Report Overview

Rising demand for liquid biopsies patients is favoring non-Invasive cancer diagnosis, possibilities for liquid biopsy, non-invasive liquid biopsy, and Artificial Intelligence (AI) combined due to increased cancer rate could boost the growth of Middle East Liquid Biopsy Market during the forecast period between 2023 and 2029.

Middle East Liquid Biopsy Market - Industry Trends & Forecast Report, 2029

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimates Middle East liquid biopsy market size at USD 47.6 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Middle East liquid biopsy market size to grow at a significant CAGR of 12.9% reaching a value of USD 108.5 billion by 2029. Major factors driving the growth of the market are rising awareness of the availability of various non-invasive treatments along with the prevalence of cancer. Breast cancer is now the most common type of cancer diagnosed worldwide due to the rising prevalence of the disease among females. The new liquid biopsy method has several advantages, including quick results, low cost, early prognosis, overcoming tumor heterogeneity, low risk, and non-invasiveness. The adoption of liquid biopsy among patients around the Middle East is being fueled by all these advantages over conventional diagnosis, which is expected to significantly increase demand during the forecast period.

Middle East Liquid Biopsy Market

Middle East Liquid Biopsy Market - Overview

A liquid biopsy is a method for identifying and following the progression of diseases like cancer that involves taking a sample of biological tissue while it is still liquid and analyzing it. Liquid biopsy directly utilizes two advancements in medical science: human genome sequencing and increasing sensitivity of detection methods and assays. With liquid biopsies, the painful tissue sample extraction is not necessary, so there is no after-op discomfort. For instance, most of the liquid samples used in the method are blood and urine, both of which can be collected easily and without much pain. But some instances involve grueling procedures, like spinal fluid. Thus, liquid biopsy helps patients feel less pain-related anxiety. Additionally, it provides a safe and effective substitute for patients who are unable to undergo a tissue biopsy due to the risks involved, such as those with lung cancer whose tumors are too dangerously close to the heart.

Growth Drivers

Investments by the government in healthcare infrastructure

Federal government's increased funding is expected to drive the market's growth rate. High return on investment guaranteed by research activities will benefit the market. Government initiatives to raise awareness, particularly in developing economies, an increase in personal disposable income, the introduction of technologically driven products in hospitals, increased investment in the development of advanced medical products and devices, and an increase in demand for non-invasive surgical procedures all have a positive impact on the market growth rate.

Knowledge of research and development

Rising investment in research and development, particularly in developed and developing economies, is expected to further open lucrative market expansion opportunities for medical instruments and devices. The market growth rate is also being boosted by pharmaceutical and biopharmaceutical countries' research and development capabilities for the incorporation of cutting-edge technologies in healthcare facilities.

Restraints

Positives and False Negatives Results

High costs associated with R&D capabilities, limited infrastructure, and lower sensitivity of certain liquid biopsies are expected to stymie market growth. In addition, a lack of favorable reimbursement scenarios and technology penetration in developing economies, the need for large capital investments to set up production facilities, the low sensitivity and specificity limitations of liquid biopsy, and a lack of suitable infrastructure in low- and middle-income countries are expected to pose challenges to the market during the forecast period of 2022-2029.

Impact of COVID-19 on Middle East Liquid Biopsy Market

The COVID-19 pandemic had a significant impact on market growth and revenue. The current market assessment considered information provided by market key opinion leaders on both the supply and demand sides. Although manufacturers experienced low-scale losses because of decreased demand, the losses experienced in the first two quarters of FY2020–2021 were offset by higher demand in the following two-quarters of FY2021. However, the industry is still expected to be significantly impacted between 2020 and 2022. The low number of cancer patients in hospitals and diagnostic laboratories has had a significant impact on Exact Sciences' Cologuard test sales.

Middle East Liquid Biopsy Market

Segmental Coverage

Middle East Liquid Biopsy Market - By Technology

Middle East liquid biopsy market is divided into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Other Technologies. In terms of revenue, the multi-gene-parallel Analysis (NGS) segment dominates the Middle East liquid biopsy market, and it is expected that it will continue to dominate during the forecast period. NGS technology can identify a wide range of mutations that might contribute to tumorigenesis as well as identify potential resistance mechanisms that might have emerged from pre-existing clones after therapy. Recent rapid advancements in NGS technology have resulted in a significant cost reduction for high-accuracy sequencing. This technology enables the screening of unidentified variants and is used in targeted panels for the precise and highly sensitive detection of ctDNA mutations.

Middle East Liquid Biopsy Market Share

Middle East Liquid Biopsy Market - By Workflow

On basis of workflow, Middle East liquid biopsy market is divided into Sample Preparation, Library Preparation, Sequencing, Data Analysis. Due to an increasing number of cancer patients, the library preparation segment dominates the Middle East liquid biopsy market (by workflow). Cancer is a leading cause of death, according to World Health Organization data, with nearly 10 million deaths reported in 2020.

Middle East Liquid Biopsy Market – By Usage

On basis of usage, Middle East liquid biopsy market is divided into Research Use Only (RUO), Clinical); By Sample (Blood, Urine, Saliva). In terms of usage, the research use-only market segment dominates the Middle East liquid biopsy market. Academic research and business collaboration in the Middle East region are credited with this growth. Furthermore, the development of the Middle East liquid biopsy market is being aided by technological advancement in RUO products.

Middle East Liquid Biopsy Market – By Sample

On basis of the sample, Middle East liquid biopsy market is divided into Blood, Urine, Saliva.

Middle East Liquid Biopsy Market – By Circulating Biomarker

On basis of the circulating biomarker, Middle East liquid biopsy market is divided into Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles, Other Circulating Biomarkers.

Middle East Liquid Biopsy Market – By Product

On basis of the product, Middle East liquid biopsy market is divided into Tests/Services, Kits and Consumables, and Instruments. The tests/services segment dominates the Middle East liquid biopsy market owing to continued significant investments by healthcare companies to meet industry demand for tests/services, as well as the growing adoption of liquid biopsy tests among major end users.

Competitive Landscape

Middle East liquid biopsy market is fiercely competitive, with Bio-Rad Laboratories, Inc., Bioscience Institute S.p.A., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., PerkinElmer Inc., QIAGEN N.V., Sysmex Corporation, Thermo Fisher Scientific Inc, and Other Prominent Players. The key strategies used by these market leaders are new product launches, mergers & acquisitions, and alliances. To grow their market share, these companies are also focusing on investing in innovations, collaborations, and expansions.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Million

Market Coverage

Middle East

Product/ Service Segmentation

Technology, Workflow, Usage, Sample, Circulating Biomarker, Product 

Key Players

Bio-Rad Laboratories, Inc., Bioscience Institute S.p.A., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., PerkinElmer Inc., QIAGEN N.V., Sysmex Corporation, Thermo Fisher Scientific Inc.

 

By Technology

  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • Fluorescence In-Situ Hybridization (FISH)

  • Other Technologies

By Workflow

  • Sample Preparation

  • Library Preparation

  • Sequencing

  • Data Analysis

By Usage

  • Research Use Only (RUO)

  • Clinical

By Sample

  • Blood

  • Urine

  • Saliva

By Circulating Biomarker

  • Circulating Tumor Cells (CTCs)

  • Cell-Free DNA (cfDNA)

  • Circulating Cell-Free RNA

  • Exosomes and Extracellular Vesicles

  • Other Circulating Biomarkers

By Product

  • Tests/Services

  • Kits and Consumables

  • Instruments

 
  1. Research Framework
    1. Research Objective
    2. Liquid Biopsy Overview
    3. Market Segmentation
  2. Executive Summary
  3. Middle East Liquid Biopsy Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Demand for Liquid Biopsies Rises Due to Increased Cancer Rate
        2. Patients Are Increasingly Favoring Non-Invasive Cancer Diagnosis
        3. Possibilities for Liquid Biopsy
      2. Restraints
        1. Positives and False Negatives Results
      3. Opportunities
        1. Non-Invasive Liquid Biopsy and Artificial Intelligence (AI) Combined
      4. Challenge
    3. Recent Developments/Technological Advancement
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Middle East Liquid Biopsy Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Technology
        1. Polymerase Chain Reaction (PCR)
        2. Next-Generation Sequencing (NGS)
        3. Fluorescence In-Situ Hybridization (FISH)
        4. Other Technologies
      2. By Workflow
        1. Sample Preparation
        2. Library Preparation
        3. Sequencing
        4. Data Analysis
      3. By Usage
        1. Research Use Only (RUO)
        2. Clinical
      4. By Sample
        1. Blood
        2. Urine
        3. Saliva
      5. By Circulating Biomarker
        1. Circulating Tumor Cells (CTCs)
        2. Cell-Free DNA (cfDNA)
        3. Circulating Cell-Free RNA
        4. Exosomes and Extracellular Vesicles
        5. Other Circulating Biomarkers
      6. By Product
        1. Tests/Services
        2. Kits and Consumables
        3. Instruments
  5. Middle East & Africa Middle East Liquid Biopsy Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Technology
      2. By Workflow
      3. By Usage
      4. By Sample
      5. By Circulating Biomarker
      6. By Product
      7. By Country
        1. Saudi Arabia
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        2. UAE
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        3. Qatar
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        4. Kuwait
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        5. South Africa
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        6. Nigeria
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        7. Egypt
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
        8. Rest of Middle East & Africa
          1. By Technology
          2. By Workflow
          3. By Usage
          4. By Sample
          5. By Circulating Biomarker
          6. By Product
  6. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Middle East Liquid Biopsy Company Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  7. Impact of Covid-19 on Global Middle East Liquid Biopsy Market
  8. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Bio-Rad Laboratories, Inc.
    2. Bioscience Institute S.p.A.
    3. Eurofins Scientific
    4. F. Hoffmann-La Roche Ltd
    5. Guardant Health
    6. Illumina, Inc.
    7. Natera, Inc.
    8. NeoGenomics Laboratories, Inc.
    9. PerkinElmer Inc.
    10. QIAGEN N.V.
    11. Sysmex Corporation
    12. Thermo Fisher Scientific Inc
    13. Other Prominent Players
  9. Key Strategic Recommendations
  10. Research Methodology
    1.  Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3.  Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.  Breakdown of Primary Research Respondents, By Region
    5.  Assumptions & Limitations

 

*Financial information in case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.          

 

 

List of Figures

 

Figure 1        Middle East & Africa Liquid Biopsy Segmentation

Figure 2        Middle East & Africa Liquid Biopsy Market Value Chain Analysis

Figure 3        Company Market Share Analysis, 2021

Figure 4        Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 5        Middle East & Africa Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 6        Middle East & Africa Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 7        Middle East & Africa Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 8        Middle East & Africa Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 9        Middle East & Africa Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 10       Middle East & Africa Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 11       Middle East & Africa Liquid Biopsy Market Share, By Country, By Value, 2019–2029

Figure 12       Saudi Arabia Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 13       Saudi Arabia Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 14       Saudi Arabia Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 15       Saudi Arabia Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 16       Saudi Arabia Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 17       Saudi Arabia Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 18       Saudi Arabia Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 19       UAE Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 20       UAE Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 21       UAE Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 22       UAE Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 23       UAE Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 24       UAE Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 25       UAE Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 26       Qatar Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 27       Qatar Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 28       Qatar Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 29       Qatar Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 30       Qatar Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 31       Qatar Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 32       Qatar Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 33       Kuwait Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 34       Kuwait Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 35       Kuwait Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 36       Kuwait Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 37       Kuwait Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 38       Kuwait Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 39       Kuwait Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 40       South Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 41       South Africa Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 42       South Africa Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 43       South Africa Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 44       South Africa Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 45       South Africa Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 46       South Africa Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 47       Nigeria Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 48       Nigeria Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 49       Nigeria Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 50       Nigeria Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 51       Nigeria Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 52       Nigeria Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 53       Nigeria Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 54       Egypt Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 55       Egypt Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 56       Egypt Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 57       Egypt Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 58       Egypt Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 59       Egypt Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 60       Egypt Liquid Biopsy Market Share, By Product, By Value, 2019–2029

Figure 61       Rest of Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Figure 62       Rest of Middle East & Africa   Liquid Biopsy Market Share, By Technology, By Value, 2019–2029

Figure 63       Rest of Middle East & Africa Liquid Biopsy Market Share, By Workflow, By Value, 2019–2029

Figure 64       Rest of Middle East & Africa Liquid Biopsy Market Share, By Usage, By Value, 2019–2029

Figure 65       Rest of Middle East & Africa Liquid Biopsy Market Share, By Sample, By Value, 2019–2029

Figure 66       Rest of Middle East & Africa Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2019–2029

Figure 67       Rest of Middle East & Africa Liquid Biopsy Market Share, By Product, By Value, 2019–2029

 

List of Tables

 

Table 1         Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 2         Middle East & Africa Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 3         Middle East & Africa Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 4         Middle East & Africa Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 5         Middle East & Africa Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 6         Middle East & Africa Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 7         Middle East & Africa Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 8         Middle East & Africa Liquid Biopsy Market Size, By Country, By Value, 2019–2029

Table 9         Saudi Arabia Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 10        Saudi Arabia Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 11        Saudi Arabia Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 12        Saudi Arabia Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 13        Saudi Arabia Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 14        Saudi Arabia Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 15        Saudi Arabia Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 16        UAE Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 17        UAE Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 18        UAE Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 19        UAE Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 20        UAE Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 21        UAE Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 22        UAE Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 23        Qatar Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 24        Qatar Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 25        Qatar Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 26        Qatar Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 27        Qatar Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 28        Qatar Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 29        Qatar Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 30        Kuwait Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 31        Kuwait Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 32        Kuwait Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 33        Kuwait Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 34        Kuwait Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 35        Kuwait Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 36        Kuwait Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 37        South Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 38        South Africa Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 39        South Africa Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 40        South Africa Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 41        South Africa Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 42        South Africa Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 43        South Africa Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 44        Nigeria Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 45        Nigeria Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 46        Nigeria Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 47        Nigeria Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 48        Nigeria Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 49        Nigeria Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 50        Nigeria Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 51        Egypt Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 52        Egypt Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 53        Egypt Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 54        Egypt Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 55        Egypt Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 56        Egypt Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 57        Egypt Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 58        Rest of Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2019–2029

Table 59        Rest of Middle East & Africa Liquid Biopsy Market Size, By Technology, By Value, 2019–2029

Table 60        Rest of Middle East & Africa Liquid Biopsy Market Size, By Workflow, By Value, 2019–2029

Table 61        Rest of Middle East & Africa Liquid Biopsy Market Size, By Usage, By Value, 2019–2029

Table 62        Rest of Middle East & Africa Liquid Biopsy Market Size, By Sample, By Value, 2019–2029

Table 63        Rest of Middle East & Africa Liquid Biopsy Market Size, By Circulating Biomarker, By Value, 2019–2029

Table 64        Rest of Middle East & Africa Liquid Biopsy Market Size, By Product, By Value, 2019–2029

Table 65        Bio-Rad Laboratories, Inc. Company Overview

Table 66        Bio-Rad Laboratories, Inc. Financial Overview

Table 67        Bioscience Institute S.p.A. Company Overview

Table 68        Bioscience Institute S.p.A. Financial Overview

Table 69        Eurofins Scientific Technologies Co., Ltd.  Company Overview

Table 70        Eurofins Scientific Technologies Co., Ltd.  Financial Overview

Table 71        F. Hoffmann-La Roche Ltd Company Overview

Table 72        F. Hoffmann-La Roche Ltd Financial Overview

Table 73        Guardant Health Company Overview

Table 74        Guardant Health Financial Overview

Table 75        Illumina, Inc. Company Overview

Table 76        Illumina, Inc. Financial Overview

Table 77        Natera, Inc. Company Overview

Table 78        Natera, Inc. Financial Overview

Table 79        NeoGenomics Laboratories, Inc.  Company Overview

Table 80        NeoGenomics Laboratories, Inc.  Financial Overview

Table 81        PerkinElmer Inc. Company Overview

Table 82        PerkinElmer Inc. Financial Overview

Table 83        QIAGEN N.V. Company Overview

Table 84        QIAGEN N.V.  Financial Overview

Table 85        Sysmex Corporation Company Overview

Table 86        Sysmex Corporation Financial Overview

 

Market Segmentation

By Technology

  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • Fluorescence In-Situ Hybridization (FISH)

  • Other Technologies

By Workflow

  • Sample Preparation

  • Library Preparation

  • Sequencing

  • Data Analysis

By Usage

  • Research Use Only (RUO)

  • Clinical

By Sample

  • Blood

  • Urine

  • Saliva

By Circulating Biomarker

  • Circulating Tumor Cells (CTCs)

  • Cell-Free DNA (cfDNA)

  • Circulating Cell-Free RNA

  • Exosomes and Extracellular Vesicles

  • Other Circulating Biomarkers

By Product

  • Tests/Services

  • Kits and Consumables

  • Instruments

 
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The Test/Services segment holds the highest market share in the Middle East Liquid Biopsy Market by product.
Ans: Middle East Liquid Biopsy Market size was estimated at USD 47.6 billion in 2022.
Ans: The Next-Generation Sequencing (NGS) segment accounts for the highest market share in the Middle East Liquid Biopsy Market by technology.
Ans: Major factors driving the growth of Middle East Liquid Biopsy Market include rising demand for liquid biopsies patients favoring non-Invasive cancer diagnosis, possibilities for liquid biopsy, non-invasive liquid biopsy, and Artificial Intelligence (AI) combined due to increased cancer rate.
Ans: Key players in Middle East Liquid Biopsy Market include Bio-Rad Laboratories, Inc., Bioscience Institute S.p.A., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., PerkinElmer Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc.